Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
2
29%
Ph phase_3
2
29%

Phase Distribution

3

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 22 (28.6%)
Phase 32 (28.6%)

Trials by Status

completed686%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

NCT00054106
completedphase_2

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

NCT00258375
completedphase_2

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00258388
completedphase_1

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

NCT00471432
completedphase_3

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

NCT01578655
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00054106Phase 1

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Completed
NCT00258375Phase 2

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Completed
NCT00258388Phase 2

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Completed
NCT00471432Phase 1

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Completed
NCT01578655Phase 3

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Completed
NCT01083615Phase 3

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Terminated
NCT00138658Phase 1

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7